GovChime
Notice ID: 2c3db744f2bf4da2bdda3f7cc48b10dfAward NoticeAwarded

6505--FY27 F18 Florebetapir

Awarded on November 6, 2026. The description is published on SAM.gov: Full description on SAM.gov.

Awarded tounder 36C24827D0013 (source: SAM.gov award notice)• $1.4M

Overview

Posted
November 6, 2026
Notice type
Award Notice

Notice details

Office
248-NETWORK CONTRACT OFFICE 8 (36C248)
Last updated
Nov 6, 2026
First published
Last updated on SAM.gov
Award date
Nov 6, 2026
Award amount (SAM.gov award notice)
$1.4M

Identifiers

Solicitation number
36C24826Q1256
Notice ID
2c3db744f2bf4da2bdda3f7cc48b10df
Award number (PIID)
36C24827D0013

Description

No description in the SAM.gov data feed for this notice.

Full description on SAM.gov

Award Overview

Award Number

36C24827D0013

Award Amount (SAM.gov award notice)

$1.4M

Award Date

Nov 6, 2026

Awardee

Awardee UEI

Z63RLN31BEE5

Awardee CAGE Code

1TQ01

Awardee Address

KNOXVILLE, TN 37932, TN

Original Solicitation

Notice ID: 2c3db744f2bf4da2bdda3f7cc48b10df

Posted Date: Nov 6, 2026

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

1
  • 36C24827N0140
    PETNET SOLUTIONS, INC.
    Department of Veterans AffairsNAICS 325412
    $288.2KSigned Nov 6, 2026

More From This Vendor

Top 5 most recent

5
  • 36C24627N0311
    PETNET SOLUTIONS, INC.
    Department of Veterans AffairsNAICS 325412
    $385.2KSigned Nov 13, 2026
  • 36C24827N0140
    PETNET SOLUTIONS, INC.
    Department of Veterans AffairsNAICS 325412
    $288.2KSigned Nov 6, 2026
  • 36C24626D0028
    PETNET SOLUTIONS, INC.
    Department of Veterans AffairsNAICS 325412
    —Signed Nov 3, 2026
  • 36C24627N0311
    PETNET SOLUTIONS, INC.
    Department of Veterans AffairsNAICS 325412
    $405.8KSigned Nov 3, 2026
  • 36C25027N0109
    PETNET SOLUTIONS INC
    Department of Veterans AffairsNAICS 325412
    $696.0KSigned Oct 30, 2026

Contacts

Contracting Officer

Primary Contact

Benjamin M. Amato
Contracting Officer

Documents

Files (3)

  • Justification for Sole Source_.pdf

    890 KBAdded in Award Notice version 2Posted
    Download
  • 36C24827D0013_1.docx

    13 KBAdded in Award Notice version 2Posted
    Download
  • 36C24826Q1256.docx

    16 KBAdded in Special Notice version 1Posted
    Download

Lifecycle

  1. 1
    Version 1Special Notice

    6505--FY27 F18 Florebetapir

    Notice 9fa756f10d6642a08eac77144b065236 on SAM.gov

  2. 2
    Version 2Award NoticeCurrent

    Type changed from Special Notice to Award Notice

    6505--FY27 F18 Florebetapir

    Notice 2c3db744f2bf4da2bdda3f7cc48b10df on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT TO PETNET SOLUTIONS, INC., located at 810 Innovation Dr. Knoxville, TN 37932 for F18 Florbetapir for the Orlando Healthcare System, 13800 Veterans Way, Orlando, FL 32827. This procurement is being conducted in accordance with 41 USC 3304(a)(1) as implemented by FAR 6.302-1. The North American Industry Classification System code for this procurement is 325412 and the small business administrative size standard is 1,300 Employees. The current Federal Acquisition Circular and the Revolutionary Federal Acquisition Regulation Overhaul dated 07/01/2026. If vendors believe they have the technical capability to meet this specific need, submit a complete technical package, which provides clear and convincing evidence that they can meet the Government s requirement. Submit your response to this notice no later than 09/29/2026, 1:00 PM Eastern Standard Time to Contracting Officer, Benjamin Amato, benjamin.amato@va.gov. Any responses received will be considered for the purposes of validating the requirement as sole source. The Government will not pay for information submitted. This will be the only notice of the Government s intent to solicit, and award to one source to satisfy this requirement.
100%
Special Notice09/29/2026
THIS REQUEST FOR INFORMATION (RFI) / SOURCES SOUGHT NOTICE IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES. THIS IS NOT A SOLICITATION. SUBMISSION OF INFORMATION ABOUT PRICING, DELIVERY, THE MARKET, AND CAPABILITIES IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI FOR PLANNING PURPOSES IN ACCORDANCE WITH (IAW) FAR 15.201(e). DISCLAIMER This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. SOURCES SOUGHT/RFI DESCRIPTION This is NOT a solicitation announcement. This is a Sources Sought Notice / RFI only. The purpose of this Sources Sought Notice / RFI is to gain information about potential qualified sources and their size classification relative to NAICS 325412 (size standard of 1,300 Employees). Responses to this Sources Sought Notice / RFI will be used by the Government to make appropriate acquisition decisions. After review of the responses to this Sources Sought Notice / RFI, further RFIs and/or a solicitation or other announcements may be published. The Department of Veterans Affairs (VA) is seeking sources capable of providing Lenalidomide medication in multiple dosage strengths. STATEMENT OF WORK LENALIDOMIDE MEDICATION Introduction The Department of Veterans Affairs requires a Health Service Area (HSA) 5.3 Blanket Purchase Agreement (BPA) for Lenalidomide. Lenalidomide is an oral immunomodulatory medication that treats several types of blood cancers. Contractor is to provide Lenalidomide and deliver to participating HSA 5.3 VA Medical Centers (VAMCs). Participating HSA 5.3 VAMCs: VA Albuquerque Healthcare System (501) 1501 San Pedro Drive SE Albuquerque, NM 87108 VA Long Beach Healthcare System (600) 5901 East 7th Street Long Beach, CA 90822 VA Loma Linda Healthcare System (605) 11201 Benton Street Loma Linda, CA 92357 VA Phoenix Healthcare System (644) 650 E Indian School Road Phoenix, AZ 85012 VA Prescott Healthcare System (649) 500 N. State Highway 89 Prescott, AZ 86313 VA San Diego Healthcare System (664) 3350 La Jolla Village Drive San Diego, CA 92161 VA Tucson Healthcare System (678) 3601 S 6th Avenue Tucson, AZ 85723 VA Greater Los Angeles Healthcare System (691) 11301 Wilshire Blvd Los Angeles, CA 90073 Ordering Participating VA Medical Centers shall place orders through an approved purchase order (PO) per station. An approved purchase order shall be signed by a warranted Contracting Officer (CO). Dispensing: Lenalidomide is under Food and Drug Administration s Risk Evaluation and Mitigation Strategy (REMS) program. The contractor must hold REMS certification to dispense. Schedule of Supplies: Line Item Description 0001 LENALIDOMIDE 2.5MG CAP,ORAL 0002 LENALIDOMIDE 5MG CAP,ORAL 0003 LENALIDOMIDE 10MG CAP,ORAL 0004 LENALIDOMIDE 15MG CAP,ORAL 0005 LENALIDOMIDE 20MG CAP,ORAL 0006 LENALIDOMIDE 25MG CAP,ORAL Station Estimated number of patients on FY 26 501 14 600 27 605 18 644 32 649 13 664 28 678 30 691 26 There is not a contractual statement of precise quantities that the Government will order under this BPA. The Government will only pay for quantities that are actually ordered and for which services are fulfilled of each delivery order per station. Above estimated number for patients is based on historical data from previous years. As the required dosage will vary depending on individual patient and provider decisions, the Government is unable to specify the exact quantity needed for each dosage. The contractor is to provide pricing for all dosage strengths, and each station will place orders as needed at the prices negotiated under this contract. Period of Performance: 1-year after award Delivery: The contractor shall be responsible for the delivery of medication to specified location upon ordering in accordance with the requirements outlined. The medication should be provided in the required quantities and formulation as specified. The contractor must ensure proper handling, storage, and transportation conditions (temperature control if required) of the medication to maintain its integrity and compliance with all applicable regulations. Payments: Payments shall be made upon delivery and acceptance by individual medical centers. The contractor shall use the purchase order (PO) number when submitting for payment through Tungsten network website https://portal.tungsten-network.com. The list of DRAFT characteristics is intended to be descriptive, not restrictive, of the supplies/services that are required. If your company is interested and capable of providing the required supplies/services, please provide the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: (1) Submit your capabilities statement illustrating how your organization can/cannot meet the list of SOW requirements. For instances where your company cannot meet the SOW requirement(s), please explain. For instances where your company can meet the SOW requirement(s), please show how your company meets/exceeds each requirement. (2) Please review the list of SOW requirements and provide any additional feedback or suggestions. If none, please reply as N/A. (3) Please indicate the size status and representations of your business, such as but not limited to: Service-Disabled Veteran-Owned Small Business (SDVOSB), Veteran-Owned Small Business (VOSB), HUBZone, Woman Owned Small Business (WOSB), Large Business, etc. (4) Is your company considered small under the NAICS code identified in this RFI? (5) Are you the manufacturer, authorized distributor, and/or can your company provide a solution to the required supplies/services described in the list of SOW? (6) If you are a large business, do you have any designated/authorized distributors? If so, please provide their company name, telephone, point of contact and size status (if available). (7) If you re a small business and you are an authorized distributor/reseller for the items identified above, do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified. (8) Limitations on Subcontracting: How does your business ensure compliance with the limitations on subcontracting as outlined in 13 CFR § 125.6? (9) Are the items you are identifying/providing considered Commercial of the Shelf (COTS) items as defined in FAR Part 2.101 under commercial items? (10) Non-Manufacturer Rule: If applicable, can you confirm your business complies with the Non-Manufacturer rule? Specifically, does your company: Provide a product from a small business manufacturer or processor? Not exceed 500 employees? Primarily engage in the retail or wholesale trade and normally sell the type of item being supplied? Take ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice? (11) Please indicate whether your product conforms to the requirements of the Buy American Act? (12) What is your lead time to deliver a single unit with all components? Is there scale in lead time with greater quantities? Please elaborate. (13) What is estimated life span of your solution? What support/services does that entail? (14) Does your proposed equipment have FDA clearance? Please specify what FDA clearance(s) have been obtained. (15) Does your organization offer a leasing solution? Please elaborate. (16) Does your company have a Federal Supply Schedule (FSS) GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract? If so, please provide the contract number(s). (17) If you are an FSS GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract holder, are all the items/solutions you are providing information about available on your schedule/contract? Please state if all or some items are available on the contract. (18) General pricing of your products/solution is encouraged. Pricing will be used for the purpose of market research only. It will not be used to evaluate for any type of award. (19) Please provide your SAM.gov Unique Entity ID/Cage Code number. Responses to this notice shall be submitted via email to Hestia.Sim@va.gov. Telephone responses will not be accepted. Responses must be received no later than Friday, November 12, 2026, by 10AM Pacific Local Time. All responses to this Sources Sought/RFI will be used for planning purposes only. Responses to this Sources Sought Notice / RFI are not considered a request to be added to a prospective bidders list or to receive a copy of the solicitation. If further RFIs and/or a solicitation or other announcement is issued as a result of the information provided from this RFI, all interested parties must respond to the specific posting separately IAW the specifications of that announcement.
87%
Market Research11/12/2026
SOURCES SOUGHT NOTICE (36C25027Q0052) Low Energy Radiopharmaceuticals (Non-FDG F-18 Agents), Unit Doses VA Northeast Ohio Healthcare System (Cleveland, OH) and VA Kent Imaging and Infusion Center (Kent, OH) Notice Type: Sources Sought (Market Research Only) Contracting Office: Department of Veterans Affairs NAICS Code: 325412 Pharmaceutical Preparation Manufacturing Small Business Size Standard: 1,300 employees Product Service Code (PSC): 6505 Drugs and Biologicals Place of Performance: Hot Lab Room B-C432, 10701 East Blvd., Cleveland, OH 44106; and Hot Lab Room B109, 3838 Cascades Blvd., Kent, OH 44240 Anticipated Period of Performance: Base: 01/01/2027 12/31/2027, plus four (4) 12-month option years (through 12/31/2031) Response Due Date/Time: 9:00 AM Eastern Time, Tuesday, November 3, 2026 to: Robert.Blasko@va.gov 1. PURPOSE / DISCLAIMER This is a Sources Sought Notice (SSN) issued for market research purposes only in accordance with FAR Part 10. It is NOT a solicitation, a request for proposal, a request for quotation, or an invitation for bid, and it does not commit the Government to issue a solicitation or award any contract. The Government will not pay for any information submitted in response to this notice, and responses will not be returned. Submitting a response does not guarantee participation in any future solicitation. The purpose of this notice is to identify qualified sources including the extent of participation by Service-Disabled Veteran-Owned Small Businesses (SDVOSBs), Veteran-Owned Small Businesses (VOSBs), and other small business concerns capable of meeting the requirement described below. Responses will assist the Government in determining the appropriate acquisition strategy (including any Veterans First / Rule of Two set-aside determination under VAAR 819.70) and will be used to support acquisition planning under FAR Part 10 and VAAR Part 810. This requirement is being conducted under the VA's health-care-resources sharing authority at 38 U.S.C. 8153 and Public Law 104-262. 2. BACKGROUND AND SCOPE The VA Northeast Ohio Healthcare System and the VA Kent Imaging and Infusion Center require unit-dose, patient-specific low energy radiopharmaceutical products (non-fluorodeoxyglucose F-18 agents) to support routine (non-emergent) and emergent diagnostic nuclear medicine imaging and limited therapeutic procedures. All doses must be compounded and calibrated by or under the supervision of a certified Nuclear Pharmacist and prepared within the required guidelines of the Board of Pharmacy, specifically USP and USP as appropriate. The contractor must follow generally accepted industry standards and the regulations of the applicable governing bodies, which may include the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Food and Drug Administration (FDA), the Nuclear Regulatory Commission (NRC), the Centers for Disease Control and Prevention (CDC), the United States Pharmacopeia (USP), and The Joint Commission (JC). Delivery requirement: The contractor must support both routine and emergent orders (Emergencies). Emergencies may be requested during and outside of regular work hours (Monday through Friday, 06:30 a.m. 4:30 p.m.) and require delivery within 120 minutes after receipt of a phoned, faxed, or electronic order from the VA. The VA also requires prompt processing of Tc-99m tagged white blood cell (WBC) orders. Quantities are estimates and may vary based on patient demand. 3. REQUIRED LICENSURE STATEMENT Interested parties must already possess all licenses, registrations, and authorizations required to receive, possess, compound, prepare, transport, distribute, and dispose of the radioactive byproduct material / radiopharmaceutical isotopes described in this notice, and must be regularly established in the business of providing radionuclides. At a minimum, respondents must hold a current, unrevoked Nuclear Regulatory Commission (NRC) and/or applicable Agreement State radioactive materials license authorizing production and distribution of radiopharmaceuticals for human administration, and the authority to receive and dispose of radioactive waste, together with all applicable FDA, U.S. Department of Transportation (DOT), and state and local authorizations. Respondents should confirm they currently hold such licensure (and, where applicable, identify the issuing authority and license type) as part of their response. Respondents are not required to submit the full license with this SSN but must affirmatively state that current, valid licensure is in place; copies may be required at the solicitation/award stage. 4. ESTIMATED REQUIREMENT (ANNUAL ESTIMATES) The following unit-dose radiopharmaceutical products are required. Quantities are annual estimates based on historical usage for one year and may vary based on patient demand. Item Description Est. Annual Qty 1 99mTc Sulfur Colloid 320 2 99mTc MDP 850 3 99mTc Mebrofenin 110 4 99mTc MAG-3 80 5 99mTc Tetrofosmin 10 6 99mTc MAA 75 7 111In Pentreotide 2 8 99mTc04- (Sodium Pertechnetate) 90 9 99mTc Sestamibi 5,000 10 99mTc White Blood Cell Labeling 90 11 111In White Blood Cell Labeling 2 12 99mTc DTPA 30 40 mCi 60 13 99mTc DTPA 0.4 0.7 mCi 5 14 I-123 Iodine Capsules 200 microcuries 90 15 I-123 Iodine Capsules 2 5 millicuries 12 16 UltraTag Kit 22 17 99mTc Filtered Sulfur Colloid: 0.5 1 millicurie 6 18 123I MIBG dose 2 19 Cold PYP vials 50 20 99mTc PYP 100 21 99mTc DMSA 2 22 67Ga Gallium Citrate 2 23 111In DTPA 2 24 99mTc HMPAO 2 25 131I Diagnostic capsule 10 26 131I Therapeutic capsule 1 3 mCi 12 27 131I Therapeutic capsule, each additional mCi 1,500 28 99mTc HDP 55 29 99mTc WBC Blood Kit (Heparin) 90 Products must be labeled with the radiopharmaceutical identity, amount/activity, concentration, preparation time, calibration time, total volume, expiration date and time, and must include a bar-code label to facilitate scanning into a Nuclear Medicine Information System (NMIS). Each syringe, vial, syringe shield, and vial shield must be correctly labeled. 5. INFORMATION REQUESTED FROM RESPONDENTS Interested and capable firms are invited to submit a response demonstrating their ability to meet this requirement. Responses must include ALL of the following: Manufacturer Authorized Distribution Letter(s) documentation establishing the respondent's authorization to distribute the applicable radiopharmaceutical product(s) (e.g., authorized distributor/dealer letter(s) from the manufacturer(s)). Manufacturer's Name(s) identify the manufacturer(s) of the radiopharmaceutical product(s) the respondent would supply. Business Size and Socioeconomic Status state whether the firm is a large or small business under NAICS 325412 (1,300-employee size standard), and identify all applicable socioeconomic categories (e.g., SDVOSB, VOSB, 8(a), HUBZone, WOSB, SDB, or other). SDVOSBs/VOSBs must be certified in the SBA Veteran Small Business Certification program (via the SBA Search for Certified Businesses (SBS)). Ability to Provide ALL Items state clearly whether the firm can provide ALL of the items listed in Section 4. If the firm can provide only a portion, identify specifically which item(s) it can and cannot supply. GSA / NAC / SAC Availability state whether the item(s) are available on a GSA Schedule, a VA National Acquisition Center (NAC) contract, or a VA Strategic Acquisition Center (SAC) / MSPV contract vehicle, and provide the applicable contract number(s) if so. SAM Unique Entity Identifier (UEI) provide the firm's SAM.gov UEI. Respondents must be actively registered in SAM.gov (www.sam.gov). Current Licensure Confirmation an affirmative statement that the firm currently holds all required NRC and/or Agreement State, FDA, and DOT licenses/authorizations to receive, compound, prepare, transport, distribute, and dispose of the radiopharmaceutical isotopes described herein (see Section 3), including the issuing authority and license type where applicable. Positive Acknowledgement of Delivery Capability a positive, affirmative statement that the firm can deliver in accordance with ALL SOW requirements, including the ability to fulfill emergent orders within 120 minutes of receipt to both the Cleveland and Kent locations, and to provide unit doses compounded/calibrated by or under a certified Nuclear Pharmacist in accordance with USP / and all applicable NRC/FDA/DOT/state regulations. Respondents are encouraged to identify the location(s) of the radiopharmacy(ies) from which they would service both sites. Additional information requested (optional but helpful): company name, address, point of contact (name, title, phone, email); a brief capability statement; and any relevant prior experience providing unit-dose radiopharmaceuticals to federal or commercial healthcare customers. 6. SUBMISSION INSTRUCTIONS Response due date/time: 9:00 AM Eastern Time, Tuesday, November 3, 2026. Responses received after this date and time may not be considered. Format: Submit responses electronically to the Contracting Officer / Contract Specialist identified in the SAM.gov posting (Robert.Blasko@va.gov) . Reference this Sources Sought Notice number (36C25027Q0052) in the subject line. Page/content: Address each item in Section 5, in order. Capability statements should be concise. Questions: Direct any questions to the point of contact listed in the SAM.gov posting (Robert.Blasko@va.gov) prior to the response due date. 7. IMPORTANT NOTES This notice does not restrict the Government to any particular acquisition approach. Based on the responses received, the Government will determine whether the requirement can be set aside for SDVOSBs, VOSBs, or other small business concerns consistent with the Veterans First Contracting Program (VAAR 819.70) and the Rule of Two, or whether another acquisition strategy is appropriate. Respondents are advised that the Nonmanufacturer Rule (13 CFR 121.406) and Limitations on Subcontracting (FAR 52.219-14 / 52.219-33) apply to any resulting SDVOSB/VOSB set-aside or sole-source award above the micro-purchase threshold. Respondents should be prepared to address their status (manufacturer vs. nonmanufacturer) under these rules. All prospective offerors must be registered in SAM.gov to be eligible for any resulting award. The applicable Buy American Act / Trade Agreements Act provisions will apply to any resulting solicitation; respondents may be required to provide a Buy American Act certificate and country-of-origin information at the solicitation stage. THIS IS A SOURCES SOUGHT NOTICE / MARKET RESEARCH ONLY NOT A SOLICITATION.
80%
Market Research11/03/2026
RFQ 36C77027Q0019 EXCEL SPREADHSHEET ATTACHED 52.225-2 BUY AMERICAN CERTIFICATE ATTACHED
68%
Solicitation11/25/2026
68%
Solicitation11/25/2026

Additional Details

Solicitation Number

36C24826Q1256

Archive Date

Nov 26, 2026

Office Address

TAMPA, FL, 33637